ClinicalTrials.gg
CompletedNCT03474731CCNUpdated Aug 29, 2024Results posted

Clinic to Community Navigation to Improve Diabetes Outcomes

An interventional study of Diabetes Self-Management Program (DSMP) and Tailored Patient Navigation (PN) only in Diabetes Mellitus, sponsored by Nancy Schoenberg. Completed at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-08-29.

Sponsored by Nancy Schoenberg · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
701
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 3,023 studies in Diabetes Mellitus with a site in United States — 289 open to participants now, 388 under way, 12 of them phase 3. Diabetes Mellitus · United States.

Enrollment
238th of 2,502
701 · median 82
Started
2018
with 114 others
No phase
1,418 of 3,023
159 open now
Registered
2,091st of 3,023
by date

Among the 3,023 studies in Diabetes Mellitus with a site in United States, this one is the 238th largest by enrollment of the 2,502 interventional ones that give a count, is one of 115 that started in 2018, is one of 1,418 with no phase, and was the 2,091st registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

289 of the 3,023 studies in Diabetes Mellitus with a site in United States are open now. Recruiting first, the newest first:

284 more — sign in →

All 289 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,023 studies in Diabetes Mellitus with a site in United States, or all of them as a file.
02

Study summary

Background and justification: Nearly 29 million Americans (9.3% of the population) have type 2 Diabetes Mellitus (T2DM) and another 86 million are considered prediabetic, 20-30% of whom will develop diabetes within five years.4,5 T2DM disproportionately affects those from lower socioeconomic status (SES) and rural backgrounds. Appalachian residents represent an extreme version of this already vulnerable population, with rates of diabetes 46% higher than national averages.6,7 The investigators have developed, pilot tested (N=41) and refined (N=48 in-depth interviews, 4 focus groups with 31 participants, and 2 CAB meetings with 16 members), a culturally appropriate, feasible, and promising intervention that combines diabetes self-management education and tailored patient navigation intervention., Goal: Our goal focuses on reducing HbA1c, BMI, blood pressure, lipids, and waist circumference and improving T2DM self-management and clinic attendance. Leveraging local assets, including faith communities, local health facilities, trained community health workers, and social support, the investigators will expand a promising and refined pilot study and assess outcomes, satisfaction and cost effectiveness. Innovation and impact: The proposed project is among the first RCT to combine the two most influential approaches to diabetes control-- self-management education and tailored patient navigation in a community setting. The Community to Clinic Navigation (CCN) intervention has the potential to sustainably empower hard to reach populations with effective self-management education and enhance the quality of healthcare in traditionally underserved communities, greatly improving T2DM outcomes.

Read the detailed description
  1. Background: Appalachian residents maintain disproportionately high rates of Type 2 Diabetes Mellitus (T2DM) and suffer tremendous burdens from diabetic complications. The main challenges to stemming adverse outcomes from T2DM involve ensuring optimal clinical care and self-management. Because the prevalence of diabetes has tripled since 2005, the already low supply of primary care physicians combined with this tremendous chronic disease burden places huge demands on providers in rural Appalachia. Enhancing the quality and efficiency of these practices by linking to community health workers has the potential of mitigating the adverse effects of these shortages.

    Patient navigation, particularly a clinic to community navigation (CCN) model offers an innovative approach to address these inequities. Patient navigation has been implemented almost exclusively in the cancer setting, despite being promising for chronic disease management. The proposed project is, to our knowledge, the first to test a hybrid model of clinic (health promotion professional) plus community (community health worker) navigation among rural residents. Clinical patient navigation has been shown to facilitate appointment setting and return visits, may improve goal setting, and enhances some adherence (medication taking, blood glucose testing), but does not address some key psychosocial (self-efficacy, patient activation) and practical concerns (transportation, childcare, self-management) challenges. Community-based navigation programs have been shown to enhance self-efficacy, decrease community barriers to care (e.g., transportation), and improved self-management, but may be less effective in ensuring return visits and working collaboratively with the doctor.

  2. Objectives: The investigators aim to test a CCN program that may improve the most salient influences on diabetes outcomes and self-management, the health care context and the patient's home context. Specifically, the investigators will (1) recruit 1200 participants from community settings with T2DM and HbA1c levels between 9-11% and randomize them to one of three arms, DSMP; PN, or combined CCN intervention; (2) the investigators will administer three quantitative assessments. All activities will take place in Appalachia. Outcomes include physiologic data (HbA1C levels, blood pressure, lipids, waist circumference and BMI, obtained by research staff); quantitative data collection of self-management (medication taking, blood glucose, appointment adherence, diet, physical activity, foot and eye care, obtained by interviewer); and psychosocial variables (self-efficacy, patient activation, obtained by interviewer).
  3. Study Design: Behavioral randomized controlled trial, single blind design.
  4. Study Population: Eligibility criteria: Adults 18+; Appalachian residence, and HBA1c levels between 9-11%. Those who do not meet these inclusion criteria, are cognitively impaired, or who do not wish to participate will be excluded. All race/ethnicities and both genders will be included. Participants will be enrolled on a rolling basis from June 1, 2014-June 2, 2019. Participants will be involved in the study for approximately one year. The investigators anticipate a total of 1200 participants.
  5. Subject Recruitment Methods and Privacy: Participants will be recruited through churches and other community settings. If eligible (see above), project staff will call potential participants within five days to verify eligibility and determine their interest in participating in the study.
  6. Informed Consent Process: For those indicating an interest in participating, staff will visit potential participants at their home or a location of their choosing and administer the informed consent document. Study personnel for all phases of the project will provide a clear explanation of the project and invite questions. Our informed consent forms are written in a basic language. Interested participants will be asked to provide their signature on the informed consent forms. A copy of the signed consent will be provided for all participants. All forms will be read to participants to allay concerns about limited literacy. No non-English speaking or cognitively impaired participants will be recruited.
  7. Research Procedures: The consort diagram (Figure 1) below provides an estimation and visual description of the recruitment and sampling frame.

    Fig 1: Consort diagram of enrollment

    1. Once informed consent documents are completed, participants (N=1200) will undergo the baseline assessment. Baseline, posttest, and exit assessments will consist of the same measures highlighted in Table 3.
    2. There will be three arms. For those randomized to the diabetes self management program (n=435), within two weeks of initial recruitment and baseline assessment, project staff will schedule the participant to attend a group Diabetes Self-management Program, a six week, lay lead and en evidence-based diabetes home self-management program (See Table 1, DSMP contents). Staff will arrange for the group sessions of the DSMP. One session will take place every other week. Upon completion of the DSMP program, approximately three month later, clinic navigation will be implemented. For those randomized to the Patient Navigation group, within two weeks of initial recruitment and baseline assessment, project staff will schedule the participant to meet with the Community Health Worker who will strategize about insuring that patients make their doctors' appointments as scheduled. The CHW/Patient Navigator will make at least 4 calls to each participant randomized to this group. For those randomized to the combined Community to Clinic Navigation, CCN (n=435), both of the activities for the Diabetes self management education group and the Patient navigation will be conducted. At month 5-6, the posttest will take place. To assess sustainability, 3-4 months later, navigation again will take place. An interviewer will complete the exit interview in month 10-11 using the same assessments. All throughout the intervention, standard medical visits will take place.

      Fig 2: Flow diagram of intervention and control activities by month

      Table 1: DSMP contents and conduct:

      Class Number Content/Objectives./Activities

      1. Diabetes: causes, diagnosis, incidence, and prevalence Discussion using a pancreas model and the handout "Understanding Diabetes". How to talk with your doctor and being a proactive patient. Goal setting
      2. Blood glucose testing, hyperglycemia, and hypoglycemia Discussion of the blood glucose-testing procedure, review of the handouts "Hyperglycemia" and "Hypoglycemia. Goal check in
      3. Eating right for diabetes, discussion of the food pyramid and dietary strategies ; Review of handouts. Goal check in
      4. Avoiding complications: Eye care, dental care, neuropathy, hypertension Discussion of appropriate eye care, dental care, kidney care. Review of how to talk with your doctor. Goal check in
      5. Getting active: review of physical activity and foot care. Goal check in
      6. Empowerment and goal check in. Class discussion.

      Table 2: Timeline

      Activity Q1 Q2 Q3 Q4 Staff training Recruitment, informed consent, enrollment, randomization Baseline medical record review/ interview 0 CCN arm participants receive DSM sessions (6 sessions total) and navigation to clinic X X Posttest 1 0 CCN arm Navigation X Exit interview 0 CCN= clinic to community navigation (intervention arm); DSM= diabetes self-management; X= intervention activity; 0= assessment

  8. Resources: The research and intervention activities will be conducted in participants' homes, community sites, and the health clinics.
  9. Potential Risks: The potential risks from participating in the study are very small. Some risk of pain from a finger prick or psychological upset could result from responding to interview questions or the emotional distress from questions about diabetes management. The most significant risk involves any threat to confidentiality. However, all project staff will be human subjects trained and have extensive experience maintaining participant confidentiality.
  10. Safety Precautions: In each stage of the research, the investigators will make every effort to provide protection against risks. Study personnel will provide a clear explanation of the project and invite questions during enrollment. In the rare event that a participant experiences psychological distress resulting from the interview questions or from the intervention, our staff will contact Dr. Van Breeding, internal medicine physician at the MCHC. Dr. Breeding will consult with the participant, debrief and discuss the participant's concerns, and refer participants to any additional support. In addition, all project staff will receive training on how to respond to a participant who needs additional assistance with diabetes management.
  11. Benefit vs. Risk Participation in the study involves little risk for subjects in comparison to the potential benefits of adopting improving diabetes outcomes. Participants in the intervention group will receive their usual care, plus navigation from a staff person at MCHC and an evidence-based diabetes self-management program at no cost. If they are not assigned to the intervention arm, they will receive their usual diabetes care. Given the disproportionate diabetes burden experienced by Appalachian populations, implementing and evaluating this novel, theory based intervention has the potential to save many lives while advancing intervention science.
  12. Available Alternative Treatment(s): Participants will be randomized to the intervention (the standard of care plus navigation with a clinic employee and community-based navigation) OR will receive the standard treatment, which involves brief clinically-based consultation with the health care provider.
  13. Research Materials, Records, and Privacy: Two sources of data will be collected: physiologic data collection (HbA1C levels, blood pressure, lipids, and BMI); and quantitative assessments (surveys). Table 3 highlights the specific data to be collected.

Table 3: Variables Data sources and collector Main outcomes HbA1C, blood pressure, lipids, waist circumference, BMI Additional outcomes: Self-management outcomes Medication taking, blood glucose testing, appointment adherence, diet, physical activity, foot and eye care.

Assessments by UK project staff Diabetes Empowerment Scale (self-efficacy), patient activation Assessments by UK project staff Sociodemographic, self-perceived health status, depression, Clinic attendance, assessments by UK project staff

  1. Confidentiality Confidentiality of all data will be maintained by never linking paper or computer copy of data with the participants' names. A sheet with the participant's name, address, telephone number, and identification number will be kept by the Project Director and Principal Investigator separately in a locked file. Only staff members who are authorized to review files will be permitted access to the data. As part of our training, each lay health adviser and interviewer will be asked to sign a confidentiality pledge promising never to reveal, alter, or falsify survey data. This pledge is especially important in small, tight-knit rural communities. Data are held in password-protected computers and secure servers at University of Kentucky which have extensive firewalls and security measures. The investigator will keep all records (tapes, informed consent documents, and other records like completed questionnaires) for a minimum of six years after the completion of the study.
  1. Costs to Subjects: N/A for program participation. Some costs associated with transportation may occur.
  1. Data and Safety Monitoring: N/A 18. Subject Complaints: Participants will be asked to contact the investigator, Dr. Nancy Schoenberg at 859-323-8175 should they have any complaints. If they have any questions about their rights as a volunteer in this research, they will be asked to contact the staff in the Office of Research Integrity at the University of Kentucky at 859-257-9428 or toll free at 1-866-400-9428.
  1. Research Involving Non-English Speaking Subjects or Subjects from a Foreign Culture: N/A 20. HIV/AIDS Research: N/A 20. PI-Sponsored FDA-Regulated Research: N/A

Two main revisions for this trial were implemented.

  1. Timelines: Reduced the 18 month follow up to 9 months and then, ultimately, from 9 months to 6 months.
  2. Data collection for several secondary outcomes:

    1. Data for HDL, LDL, cholesterol was not collected for two reasons:
  1. lack of a scientific evidence base on the association between lipids and diabetes self-management and diabetes outcomes.
  1. The extremely high cost of such data collection. b. We ceased collecting data on clinic attendance. At baseline, we collected data on clinic attendance within the standard guideline of 3 months. To our surprise, 87% of our sample had clinic appointments consistent with recommended guidelines. Thus, we could not realistically expect any significant improvements in subsequent time periods. Such a revelation, in conjunction with the cessation of clinical operations due to COVID, made clinic attendance data collection unnecessary and unfeasible. When the project began in 2017, the uninsured population of Appalachian Kentucky dropped from 25% to 6.7%. This coverage resulted in most participants adhering to the recommendations for clinic attendance.

Several significant events undermined the original data collection plan including:

  • 24 month cessation of recruitment, data collection and intervention implementation due to COVID
  • Episodic cessation of recruitment, data collection and intervention implementation due to COVID
  • Major interruption of recruitment, data collection and intervention implementation due to natural disaster (flooding July 2022)
  • Lack of NIH approval of two supplement requests to support data collection
03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Adults (age 18+);
  • Appalachian residence, no plans to relocate out of the area in the next 18 months,
  • Willingness and ability to participate (i.e., no major cognitive impairment)
  • levels at least 6.5% or Diagnosis of Diabetes.

Exclusion criteria

Exclusion Criteria:

-

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
701 participants (actual)

Study arms

  • Experimental
    Diabetes Self-Management Program (DSMP) only

    group education classes of the Diabetes Self-Management Program, (DSMP)

    Behavioral: Diabetes Self-Management Program (DSMP)

  • Experimental
    Tailored Patient Navigation (PN) only

    assisting patients in navigation to physician offices, allowing for standard of care to follow.

    Behavioral: Tailored Patient Navigation (PN) only

  • Experimental
    DSMP AND Tailored Patient Navigation

    Both group education classes and patient navigation

    Behavioral: DSMP AND Tailored Patient Navigation

  • Active comparator
    Diabetes Self-Management Program (DSMP) Delayed

    group education classes of the Diabetes Self-Management Program, (DSMP)

    Behavioral: Diabetes Self-Management Program (DSMP) Delayed

Interventions

  • BehavioralDiabetes Self-Management Program (DSMP)

    The the Diabetes Self Management Program (DSMP) in a group setting: participants will attend a six week, evidence-based diabetes home self-management program. The goal of this arm of the project is to try to get participants to engage in better diabetes self-care (blood glucose testing, medication taking, diet, exercise, stress reduction, etc.). Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization.

  • BehavioralTailored Patient Navigation (PN) only

    Tailored Patient Navigation (PN) only: trained Community Health Workers (CHW) will meet one-on-one with participants to assess the barriers experienced in adhering to medical appointments and will implement a navigation program accordingly. The goal of this arm of the project is to try to get participants to attend recommended medical appointments. PN has been shown to improve health behavior and increase self-efficacy, all with low costs.

  • BehavioralDSMP AND Tailored Patient Navigation

    DSMP AND Tailored Patient Navigation : patient navigation followed by 6 weeks of DSMP classes after the 3 month post-test interview.

    Also known as: Clinic to Community Navigation (CCN)

  • BehavioralDiabetes Self-Management Program (DSMP) Delayed

    Groups randomized to DSMP Delayed will receive 6 weeks of DSMP classes after the 3 month post-test interview. Participants will complete biometric data and surveys at 3, 6, and 9 months post randomization.

06

What researchers measure

Primary outcomes

  1. Change in Hemoglobin A1c

    Changes in hemoglobin A1c (HbA1c) will be measured with a Bayer DCA 2000+ Analyzer (21), which has a test coefficient of variation \< 5% consistent with requirements of the National Diabetes Data Group.

    Time frame: Baseline, month 3, month 6, month 9

Secondary outcomes

  1. Change in Body Mass Index

    Change in calculated as a change in weight in kilograms divided by the square of height in meter.

    Time frame: Baseline, month 3, month 6, month 9

  2. Change in Waist Circumference

    Change in Waist circumference at the umbilical waist using the Tech-Med model cat. no. 4414.

    Time frame: Baseline, month 3, month 6, month 9

  3. Number of Participants Attending a Clinic Visit

    Number of participants with a primary care provider that attended a clinic visit with that provider within the last 3 months.

    Time frame: Baseline

  4. Change in Systolic Blood Pressure

    Change in systolic blood pressure will be reported as the average of two sphygmomanometer readings

    Time frame: Baseline, month 3, month 6, month 9

  5. Change in Diastolic Blood Pressure

    Change in diastolic blood pressure will be reported as the average of two sphygmomanometer readings

    Time frame: Baseline, month 3, month 6, month 9

  6. High Density Lipoprotein (HDL)

    blood will be drawn and HDL will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in HDL over 18 months

    Time frame: Baseline to month 9

  7. Low Density Lipoprotein (LDL)

    blood will be drawn and LDL will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in LDL over 18 months

    Time frame: Baseline to month 9

  8. Total Cholesterol

    blood will be drawn and Total cholesterol will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in total cholesterol over 18 months

    Time frame: Baseline to month 9

  9. Change in Physical Component Summary Score of SF-36

    The RAND SF-36 physical component summary (PCS) score is a domain summary score that is part of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 - 100. Higher scores indicate better health or function. The PCS score is calculated by adding up standardized, weighted scores based on eight domains of health, including physical functioning and pain: Limitations in physical activities due to health problems, Bodily pain, and Vitality (energy and fatigue). Specific scoring details are provided in Taft et al. (2001).

    Time frame: Baseline, month 3, month 6, month 9

  10. Change in Mental Component Summary Score of SF-36

    The RAND SF-36 mental component summary (MCS) score is a domain summary score that is part of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 - 100. Higher scores indicating better mental health or function. The MCS score is calculated by adding up standardized, weighted scores based on eight domains of health, including physical functioning and pain: Limitations in physical activities due to health problems, Bodily pain, and Vitality (energy and fatigue). Specific scoring details are provided in Taft et al. (2001).

    Time frame: Baseline, month 3, month 6, month 9

07

Results

Posted Aug 29, 2024

Participant flow

Participants were recruited through churches and organizations in several KY counties in Appalachian Kentucky

Participant flow — Overall Study
MilestoneDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP)DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
Started198200120183
Completed15014491138
Not completed48562945
Withdrew: Withdrawal by subject36291127
Withdrew: Covid02300
Withdrew: Participant moved from area1000
Withdrew: Lost to follow-up1131817
Withdrew: Death0100
Withdrew: Participant removed0001

Outcome measures

PrimaryChange in Hemoglobin A1c

Changes in hemoglobin A1c (HbA1c) will be measured with a Bayer DCA 2000+ Analyzer (21), which has a test coefficient of variation \< 5% consistent with requirements of the National Diabetes Data Group.

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · percentage of glycated hemoglobin
Change in Hemoglobin A1c
percentage of glycated hemoglobinDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 3-0.37 ± 0.07-0.15 ± 0.08-0.31 ± 0.12-0.20 ± 0.10
baseline to month 6-0.38 ± 0.08-0.37 ± 0.08-0.21 ± 0.14-0.20 ± 0.11
baseline to month 9-0.40 ± 0.09-0.22 ± 0.10——
SecondaryChange in Body Mass Index

Change in calculated as a change in weight in kilograms divided by the square of height in meter.

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · kg/m2
Change in Body Mass Index
kg/m2Diabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 3-0.06 ± 0.10-0.23 ± 0.10-0.44 ± 0.13-0.14 ± 0.10
baseline to month 6-0.05 ± 0.12-0.34 ± 0.13-0.57 ± 0.21-0.35 ± 0.17
baseline to month 9-0.16 ± 0.14-0.41 ± 0.14——
SecondaryChange in Waist Circumference

Change in Waist circumference at the umbilical waist using the Tech-Med model cat. no. 4414.

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · inches
Change in Waist Circumference
inchesDiabetes Self-Management Program (DSMP)Diabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 3-0.25 ± 0.16-0.41 ± 0.16-0.54 ± 0.22-0.46 ± 0.18
baseline to month 6-0.63 ± 0.18-0.89 ± 0.18-0.63 ± 0.29-0.99 ± 0.23
baseline to month 9-1.09 ± 0.19-0.73 ± 0.19——
SecondaryNumber of Participants Attending a Clinic Visit

Number of participants with a primary care provider that attended a clinic visit with that provider within the last 3 months.

Time frame:
Baseline
Reported as:
Count of participants · Participants
Number of Participants Attending a Clinic Visit
ParticipantsDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP)DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
PCP Visit in last 3 months at baseline1131187087
No Visit to PCP in last 3 months at baseline15221311
SecondaryChange in Systolic Blood Pressure

Change in systolic blood pressure will be reported as the average of two sphygmomanometer readings

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · mm Hg
Change in Systolic Blood Pressure
mm HgDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 3-4.37 ± 1.56-0.47 ± 1.58-2.97 ± 1.95-3.86 ± 1.56
baseline to month 6-4.22 ± 1.590.46 ± 1.63-6.60 ± 2.04-3.56 ± 1.66
baseline to month 9-5.85 ± 1.751.02 ± 1.85——
SecondaryChange in Diastolic Blood Pressure

Change in diastolic blood pressure will be reported as the average of two sphygmomanometer readings

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · mm Hg
Change in Diastolic Blood Pressure
mm HgDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 3-2.25 ± 0.86-1.60 ± 0.87-3.01 ± 1.30-1.12 ± 1.04
baseline to month 6-1.79 ± 0.87-1.69 ± 0.89-4.09 ± 1.33-1.07 ± 1.08
baseline to month 9-2.95 ± 0.95-3.57 ± 1.01——
SecondaryHigh Density Lipoprotein (HDL)

blood will be drawn and HDL will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in HDL over 18 months

Time frame:
Baseline to month 9

No measurements were reported for this outcome.

SecondaryLow Density Lipoprotein (LDL)

blood will be drawn and LDL will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in LDL over 18 months

Time frame:
Baseline to month 9

No measurements were reported for this outcome.

SecondaryTotal Cholesterol

blood will be drawn and Total cholesterol will be measured using a Cholestech LDX point of care machine. Data will be reported as the change in total cholesterol over 18 months

Time frame:
Baseline to month 9

No measurements were reported for this outcome.

SecondaryChange in Physical Component Summary Score of SF-36

The RAND SF-36 physical component summary (PCS) score is a domain summary score that is part of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 - 100. Higher scores indicate better health or function. The PCS score is calculated by adding up standardized, weighted scores based on eight domains of health, including physical functioning and pain: Limitations in physical activities due to health problems, Bodily pain, and Vitality (energy and fatigue). Specific scoring details are provided in Taft et al. (2001).

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · score on a scale
Change in Physical Component Summary Score of SF-36
score on a scaleDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 30.29 ± 0.64-0.74 ± 0.67-1.39 ± 0.891.00 ± 0.70
baseline to month 61.00 ± 0.69-0.40 ± 0.710.92 ± 0.931.05 ± 0.75
baseline to month 90.28 ± 0.74-1.05 ± 0.79——
SecondaryChange in Mental Component Summary Score of SF-36

The RAND SF-36 mental component summary (MCS) score is a domain summary score that is part of the 36-Item Short Form Health Survey (SF-36). Scores range from 0 - 100. Higher scores indicating better mental health or function. The MCS score is calculated by adding up standardized, weighted scores based on eight domains of health, including physical functioning and pain: Limitations in physical activities due to health problems, Bodily pain, and Vitality (energy and fatigue). Specific scoring details are provided in Taft et al. (2001).

Time frame:
Baseline, month 3, month 6, month 9
Reported as:
Mean · score on a scale
Change in Mental Component Summary Score of SF-36
score on a scaleDiabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient Navigation
baseline to month 31.67 ± 0.741.73 ± 0.774.24 ± 1.031.21 ± 0.81
baseline to month 61.56 ± 0.831.66 ± 0.854.05 ± 1.100.92 ± 0.89
baseline to month 92.67 ± 0.841.82 ± 0.89——

Adverse events

Collected over 9 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Diabetes Self-Management Program (DSMP) Only0/198 (0%)0/198 (0%)0/198 (0%)
Diabetes Self-Management Program (DSMP) Delayed1/200 (0.5%)0/200 (0%)0/200 (0%)
Tailored Patient Navigation (PN) Only0/120 (0%)0/120 (0%)0/120 (0%)
DSMP AND Tailored Patient Navigation0/183 (0%)0/183 (0%)0/183 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Diabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient NavigationTotal
Mean63.0 ± 11.665.3 ± 9.361.9 ± 13.362.7 ± 11.263.4 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Diabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient NavigationTotal
Female13612176116449
Male62794467252
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Diabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient NavigationTotal
Hispanic or Latino11114
Not Hispanic or Latino197199119182697
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Diabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient NavigationTotal
American Indian or Alaska Native11046
Asian00101
Native Hawaiian or Other Pacific Islander00000
Black or African American8111424
White189198107175669
More than one race00101
Unknown or Not Reported00000
Region of Enrollment
Region of Enrollment(participants)Diabetes Self-Management Program (DSMP) OnlyDiabetes Self-Management Program (DSMP) DelayedTailored Patient Navigation (PN) OnlyDSMP AND Tailored Patient NavigationTotal
United States198200120183701
08

Study locations

1 site
  • University of Kentucky
    Lexington, Kentucky 40536, United States
09

References and documents

Publications

  • Smalls BL, Adegboyega A, Combs E, Rutledge M, Westgate PM, Azam MT, De La Barra F, Williams LB, Schoenberg NE. The mediating/moderating role of cultural context factors on self-care practices among those living with diabetes in rural Appalachia. BMC Public Health. 2021 Oct 2;21(1):1784. doi: 10.1186/s12889-021-11777-7. PubMed 34600524 ↗
  • Smalls BL, Lacy ME, Adegboyega A, Hieronymus L, Bacha N, Nathoo T, Westgate PM, Azam T, Westneat S, Schoenberg NE. A New Look at Barriers to Clinical Care Among Appalachian Residents Living With Diabetes. Diabetes Spectr. 2023 Winter;36(1):14-22. doi: 10.2337/ds22-0001. Epub 2022 Nov 18. PubMed 36818407 ↗
  • Smalls BL, Azam T, Dunfee M, Westgate PM, Westneat SC, Schoenberg N. The relationship between psychosocial factors, self-care, and blood sugar in an Appalachian population. J Appalach Health. 2023 Jan 1;4(3):1-22. doi: 10.13023/jah.0403.01. eCollection 2023. PubMed 38026048 ↗
  • Smalls BL, Adegboyega A, Combs E, Travis EW, De La Barra F, Williams LB, Schoenberg N. Evaluating the Association Between Depressive Symptoms and Glycemic Control Among Residents of Rural Appalachia. J Appalach Health. 2023 Jan 1;4(3):39-55. doi: 10.13023/jah.0403.03. eCollection 2023. PubMed 38026049 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jul 2023, 62 months.

Results were first posted in Aug 2024, 1 year 1 month after primary completion.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 62 months is above that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2017
First posted
Mar 23, 2018
StartActual
Apr 29, 2018
Primary completionActual
Jul 10, 2023
CompletionActual
Jul 10, 2023
Results first posted
Aug 29, 2024
Last update
Aug 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03474731
Lead sponsor
Nancy Schoenberg
Responsible party
Nancy Schoenberg (Principal Investigator, University of Kentucky) — Sponsor-investigator
First posted
Mar 23, 2018
Start date
Apr 29, 2018
Primary completion
Jul 10, 2023
Completion
Jul 10, 2023
Results posted
Aug 29, 2024
Last update
Aug 29, 2024

Study contacts

Nancy Schoenberg, PhD
principal investigator · University of Kentucky

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion